Haleon | MedPath

Pfizer Enters $6 Billion Licensing Deal with China's 3SBio for Novel Cancer Drug

3 days ago

• Pfizer has secured global rights (excluding China) to 3SBio's experimental cancer drug SSGJ-707 for $1.25 billion upfront, with potential additional payments of up to $4.8 billion based on developmental milestones. • SSGJ-707 is currently being evaluated for multiple cancer types including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors, with Phase III trials in China planned to begin this year. • The deal includes a $100 million equity investment in 3SBio by Pfizer, with manufacturing planned at Pfizer's facilities in North Carolina and Kansas following FDA clearance of the Investigational New Drug application.

Biocon Reports 15% Revenue Growth in Q4FY25, Launches Fifth Biosimilar in U.S. Market

14 days ago

• Biocon Group reported strong Q4FY25 performance with revenue reaching Rs 4,454 crore, up 15% year-on-year, driven by significant market share gains in biosimilars and new product launches. • The company launched Yesintek™ (ustekinumab-kfce), its fifth biosimilar in the U.S. market, which is witnessing strong physician adoption and broad formulary coverage with potential to benefit 100 million lives. • Four of Biocon's biosimilars have each recorded sales of USD 200 million in FY25, with the company's biosimilars business growing 15% for the full year and serving over 5.8 million patients globally.

Haleon Partners with Brightseed to Leverage AI for Natural Bioactive Discovery in Consumer Health

22 days ago

• Haleon and Brightseed have formed a strategic collaboration to utilize Brightseed's Forager® AI platform for discovering plant-based small molecules with potential health benefits. • The partnership will give Haleon's scientists direct access to the Forager platform, integrating AI-powered discovery into their research and product development pipelines. • Brightseed's technology has already identified plant compounds with applications in metabolic health, gut health, and immunity, aligning with Haleon's commitment to science-backed consumer health innovation.

Pfizer Completes Exit from Haleon with $3.3 Billion Stake Sale

2 months ago

• Pfizer has sold its remaining 7.3% stake in consumer healthcare company Haleon for $3.3 billion through a secondary offering and share repurchase agreement, marking its complete exit from the UK-based firm. • The sale comes two years after Haleon was spun off as an independent public company in July 2022, following the 2019 merger of GlaxoSmithKline's and Pfizer's consumer healthcare divisions. • Following Pfizer's exit, BlackRock Investment Management (UK) Ltd. will become Haleon's largest shareholder with more than a 5% stake, while Haleon will repurchase £170 million worth of its shares as part of the transaction.

FDA Approves Tremfya for Crohn's Disease and Fabhalta for Rare Kidney Disease Amid Major Pharma Acquisitions

2 months ago

• The FDA has approved Johnson & Johnson's Tremfya for moderately to severely active Crohn's disease, marking its fourth indication in the US based on robust data from phase III GALAXI and GRAVITI studies. • Novartis received FDA approval for Fabhalta to treat C3 glomerulopathy, becoming the first and only drug approved to address the underlying cause of this ultra-rare progressive kidney disease. • AstraZeneca announced plans to acquire Belgium-based EsoBiotec for up to $1 billion, while Sanofi is purchasing Dren Bio's DR-0201 for $600 million upfront to strengthen its immunology pipeline.

Siemens to Raise €1.4 Billion Through Strategic Healthineers Stake Sale

3 months ago

• Siemens plans to divest approximately 2.3% stake in Siemens Healthineers, pricing 26.5 million shares at €54.65 each, with strong investor demand exceeding available shares. • The stake sale is strategically aligned with Siemens' financing plan for its $10.6 billion Altair Engineering acquisition, demonstrating the company's portfolio optimization strategy. • The transaction represents part of a larger funding strategy, with Siemens also planning to divest €2.5 billion in Siemens Energy shares to complete the Altair acquisition funding.

Leqembi's EU Approval Faces Further Delay as EMA Re-evaluates Safety Data

6 months ago

• The European Commission has requested the EMA to re-examine Leqembi's safety data, potentially delaying its EU approval beyond the expected timeframe. • The CHMP will assess recent safety data to determine if an update to its positive opinion is needed, particularly regarding risk minimization measures. • Eisai and Biogen believe existing data support Leqembi's safety profile, reinforced by clinical use in the US and other approved regions. • Leqembi is already approved in the US, Japan, China and other countries, with a new once-monthly intravenous maintenance dose approved in the US.

Pfizer Explores Sale of Hospital Drugs Unit Amid Strategic Restructuring

6 months ago

• Pfizer has engaged Goldman Sachs to explore the potential sale of its hospital drugs unit, which generates approximately $500 million in EBITDA and focuses on antibiotics and sterile injectables. • The hospital drugs unit, established following Pfizer's $17 billion acquisition of Hospira in 2015, is being evaluated for divestiture amid pressure from activist investor Starboard Value to streamline operations. • This strategic move follows Pfizer's recent $3.26 billion stake sale in Haleon and comes as the company seeks to reduce its $61.5 billion long-term debt while responding to criticism over acquisition strategies.